Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis

Calcified Tissue International

Volumn 87, Issue 6, 2010, Pages 485-492

  Satterwhite, Julie ^a   Heathman, Michael ^a   Miller, Paul D ^b,c   Marín, Fernando ^a   Glass, Emmett V ^a   Dobnig, Harald ^d  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c University of Colorado Health Sciences Center   (United States)

^d NONE

Author keywords

Anabolic agent; Calcium pharmacodynamics; Osteoporosis therapy; Parathyroid hormone; Peptide hormone; Teriparatide pharmacokinetics

Indexed keywords

CALCIUM; PARATHYROID HORMONE[1-34]; PLACEBO;

ABDOMINAL PAIN; ANOREXIA; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CARDIOTOXICITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG RESPONSE; FEMALE; GASTRITIS; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; HYPERCALCEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PANCREATITIS; PEPTIC ULCER; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CALCIUM; FEMALE; FRACTURES, BONE; HUMANS; HYPERCALCEMIA; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; TERIPARATIDE;

EID: 78649328893     PISSN: 0171967X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00223-010-9424-6     Document Type: Article

References (25)

1. 2+ and other ions as extracellular (first) messengers Physiol Rev 71 371 411 1:CAS:528: DyaK3MXisVSksrk%3D 2006218
2. E Lewin PK Nielsen K Olgaard 1995 The calcium/parathyroid hormone concept of the parathyroid glands Curr Opin Nephrol Hypertens 4 324 333 1:STN:280:DyaK28%2FjtFymsg%3D%3D 10.1097/00041552-199507000-00007 7552098
3. JF Habener M Rosenblatt JT Potts Jr 1984 Parathyroid hormone: biochemical aspects of biosynthesis, secretion, action, and metabolism Physiol Rev 64 985 1053 1:CAS:528:DyaL2cXltVChs7c%3D 6330779
4. Kronenberg HM, Bringhurst FR, Segre GV, Potts JT Jr (2001) Parathyroid hormone biosynthesis and metabolism. In: Bilezikian JP, Marcus R, Levine MA (eds) The parathyroids: basic clinical concepts, 2nd edn. Academic Press, San Diego, pp 17-30
5. MR McClung J San Martin PD Miller R Civitelli F Bandeira M Omizo DW Donley GP Dalsky EF Eriksen 2005 Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass Arch Intern Med 165 1762 1768 1:CAS:528:DC%2BD2MXpslGgs7c%3D 10.1001/archinte.165.15.1762 16087825 (Pubitemid 41138965)
6. RM Neer CD Arnaud JR Zanchetta R Prince GA Gaich JY Reginster AB Hodsman EF Eriksen S Ish-Shalom HK Genant O Wang BH Mitlak 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434 1441 1:CAS:528:DC%2BD3MXktVSgsbw%3D 10.1056/NEJM200105103441904 11346808 (Pubitemid 32402100)
7. KG Saag E Shane S Boonen F Marin DW Donley KA Taylor GP Dalsky R Marcus 2007 Teriparatide or alendronate in glucocorticoid-induced osteoporosis N Engl J Med 357 2028 2039 1:CAS:528:DC%2BD2sXhtlWis7rP 10.1056/NEJMoa071408 18003959 (Pubitemid 350106710)
8. D Goltzman 2008 Studies on the mechanisms of the skeletal anabolic action of endogenous and exogenous parathyroid hormone Arch Biochem Biophys 473 218 224 10.1016/j.abb.2008.03.003 1:CAS:528:DC%2BD1cXlsFOgtbc%3D 10.1016/j.abb.2008.03.003 18358824
9. TM Ludden 1988 Population pharmacokinetics J Clin Pharmacol 28 1059 1063 1:STN:280:DyaL1M3hsVOntQ%3D%3D 3072349
10. LB Sheiner JL Steimer 2000 Pharmacokinetic/pharmacodynamic modeling in drug development Annu Rev Pharmacol Toxicol 40 67 95 10.1146/annurev.pharmtox. 40.1.67 1:CAS:528:DC%2BD3cXjs1yhsrg%3D 10.1146/annurev.pharmtox.40.1.67 10836128 (Pubitemid 30340674)
11. Beal SL, Sheiner LB, Boeckmann AJ (eds) (2006) NONMEM users guides (1989-2006). Icon Development Solutions, Ellicott City, MD
12. Y Yano SL Beal LB Sheiner 2001 Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check J Pharmacokinet Pharmacodyn 28 171 192 10.1023/A:1011555016423 1:STN:280:DC%2BD38%2FhtV2htg%3D%3D 10.1023/A:1011555016423 11381569 (Pubitemid 33030044)
13. Eli Lilly and Company (2009) Teriparatide [rhPTH(1-34)] (Forteo) United States package insert
14. KJ Martin KA Hruska JJ Freitag S Klahr E Slatopolsky 1979 The peripheral metabolism of parathyroid hormone N Engl J Med 301 1092 1098 1:CAS:528:DyaL3cXhvFamsA%3D%3D 10.1056/NEJM197911153012005 386126
15. D Goltzman HP Bennett M Koutsilieris J Mitchell SA Rabbani MF Rouleau 1986 Studies of the multiple molecular forms of bioactive parathyroid hormone and parathyroid hormone-like substances Recent Prog Horm Res 42 665 703 1:CAS:528:DyaL2sXmtlQ%3D 3016836
16. H Daugaard 1996 Peripheral metabolism of parathyroid hormone. Studies with isolated perfused kidneys and livers from normal and uremic rats Dan Med Bull 43 203 215 1:CAS:528:DyaK28XkvV2ntLs%3D 8813452
17. H Dobnig RT Turner 1997 The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats Endocrinology 138 4607 4612 1:CAS:528:DyaK2sXmslGrsbk%3D 10.1210/en.138.11.4607 9348185 (Pubitemid 27460894)
18. CA Frolik EC Black RL Cain JH Satterwhite PL Brown-Augsburger M Sato JM Hock 2003 Anabolic and catabolic bone effects of human parathyroid hormone (1-34) are predicted by duration of hormone exposure Bone 33 372 379 10.1016/S8756-3282(03)00202-3 1:CAS:528:DC%2BD3sXnt1GlsLc%3D 10.1016/S8756-3282(03)00202-3 13678779 (Pubitemid 37103254)
19. HR Schwietert EW Groen FA Sollie JH Jonkman 1997 Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers Clin Pharmacol Ther 61 360 376 1:CAS:528:DyaK2sXitlKksL8%3D 10.1016/S0009-9236(97)90169-7 9084461 (Pubitemid 27145438)
20. rhPTH(1-84) (Preotact) Summary of product characteristics (2007), http://www.emea.europa.eu/humandocs/PDFs/EPAR/preotact/H-659-PI-en.pdf. Accessed 30 Sep 2008
21. PD Miller JP Bilezikian M Diaz-Curiel P Chen F Marin JH Krege M Wong R Marcus 2007 Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide J Clin Endocrinol Metab 92 3535 3541 10.1210/jc.2006-2439 1:CAS:528:DC%2BD2sXhtVGqsrnL 10.1210/jc.2006-2501 17609307 (Pubitemid 47435332)
22. BM Obermayer-Pietsch F Marin EV McCloskey P Hadji J Farrerons S Boonen M Audran C Barker AD Anastasilakis WD Fraser T Nickelsen 2008 Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment J Bone Miner Res 23 1591 1600 10.1359/jbmr.080506 1:CAS:528:DC%2BD1cXht1OntLfM 10.1359/jbmr.080506 18505369
23. SL Greenspan HG Bone MP Ettinger DA Hanley R Lindsay JR Zanchetta CM Blosch AL Mathisen SA Morris TB Marriott 2007 Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial Ann Intern Med 146 326 339 17339618
24. EPAR (2007) Preotact product information. http://www.emea.europa.eu/ humandocs/Humans/EPAR/preotact/H-659-PI-en.pdf
25. EPAR (2009) Forsteo product information. http://www.emea.europa.eu/ humandocs/PDFs/EPAR/forsteo/emea-combined-h425en.pdf